Tafinlar® (dabrafenib) plus Mekinist® (trametinib) – New indication, new formulation approvals
March 16, 2023 - Novartis announced the FDA approval of Tafinlar (dabrafenib) plus Mekinist (trametinib), for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.
Top